DK1176963T3 - Anvendelse af dopamin-D3-receptorantagonister til fremstilling af lægemidler til behandling af nyrefunktionsforstyrrelser - Google Patents

Anvendelse af dopamin-D3-receptorantagonister til fremstilling af lægemidler til behandling af nyrefunktionsforstyrrelser

Info

Publication number
DK1176963T3
DK1176963T3 DK00927101T DK00927101T DK1176963T3 DK 1176963 T3 DK1176963 T3 DK 1176963T3 DK 00927101 T DK00927101 T DK 00927101T DK 00927101 T DK00927101 T DK 00927101T DK 1176963 T3 DK1176963 T3 DK 1176963T3
Authority
DK
Denmark
Prior art keywords
dopamine
drugs
manufacture
treatment
receptor antagonists
Prior art date
Application number
DK00927101T
Other languages
Danish (da)
English (en)
Inventor
Dorothea Starck
Hans-Joerg Treiber
Bernd Muehlbauer
Gerhard Gross
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Application granted granted Critical
Publication of DK1176963T3 publication Critical patent/DK1176963T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK00927101T 1999-05-07 2000-04-28 Anvendelse af dopamin-D3-receptorantagonister til fremstilling af lægemidler til behandling af nyrefunktionsforstyrrelser DK1176963T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19922443A DE19922443A1 (de) 1999-05-07 1999-05-07 Verwendung von Dopamin-D3-Rezeptorliganden zur Herstellung von Arzneimittel für die Behandlung von Nierenfunktionsstörungen
PCT/EP2000/003865 WO2000067847A2 (de) 1999-05-07 2000-04-28 Verwendung von dopamin-d3-rezeptorliganden zur herstellung von arzneimittel für die behandlung von nierenfunktionsstörungen

Publications (1)

Publication Number Publication Date
DK1176963T3 true DK1176963T3 (da) 2005-04-25

Family

ID=7908194

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00927101T DK1176963T3 (da) 1999-05-07 2000-04-28 Anvendelse af dopamin-D3-receptorantagonister til fremstilling af lægemidler til behandling af nyrefunktionsforstyrrelser

Country Status (19)

Country Link
US (2) US7098214B1 (no)
EP (1) EP1176963B1 (no)
JP (3) JP4727822B2 (no)
KR (2) KR20010112474A (no)
CN (2) CN101524356A (no)
AT (1) ATE284693T1 (no)
AU (1) AU770671B2 (no)
BR (1) BR0010337A (no)
CA (1) CA2368823C (no)
CZ (1) CZ301832B6 (no)
DE (2) DE19922443A1 (no)
DK (1) DK1176963T3 (no)
ES (1) ES2234597T3 (no)
HU (1) HU228516B1 (no)
IL (2) IL146232A0 (no)
NO (1) NO329325B1 (no)
PT (1) PT1176963E (no)
WO (1) WO2000067847A2 (no)
ZA (1) ZA200110044B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19922443A1 (de) * 1999-05-07 2000-11-09 Basf Ag Verwendung von Dopamin-D3-Rezeptorliganden zur Herstellung von Arzneimittel für die Behandlung von Nierenfunktionsstörungen
AU7989400A (en) * 1999-10-01 2001-05-10 Smithkline Beecham Corporation Compounds and methods
US20020103198A1 (en) * 2000-12-04 2002-08-01 Fliri Anton F.J Acylamino cyclopropane derivatives
ATE313534T1 (de) 2001-02-16 2006-01-15 Aventis Pharma Inc Heterocyclische substituierte carbonyl derivate und ihre verwendung als dopamin d3 rezeptor liganden
CA2438318A1 (en) * 2001-02-16 2002-08-29 Aventis Pharmaceuticals Inc. Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands
EP1392676B1 (en) * 2001-02-16 2006-12-13 Aventis Pharmaceuticals Inc. Heterocyclic urea derivatives and their use as dopamine d3 receptor ligands
DE10109866A1 (de) * 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Triazolverbindungen und deren Verwendung zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
DE10109867A1 (de) * 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Verwendung von Triazolverbindungen zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
JP2005508841A (ja) * 2001-03-29 2005-04-07 スミスクライン・ビーチャム・コーポレイション 化合物および方法
DE10131543A1 (de) * 2001-06-29 2003-01-16 Abbott Lab Pyrimidinoxyalkylpiperazine und ihre therapeutische Verwendung
HUP0103987A3 (en) * 2001-09-28 2004-11-29 Richter Gedeon Vegyeszet Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates
AU2003214920A1 (en) * 2002-02-04 2003-09-02 Millennium Pharmaceuticals Inc. Methods and compositions for treating hematological disorders
DE602004014261D1 (de) * 2003-03-17 2008-07-17 Bayer Healthcare Ag Diagnostik- und therapie- verfahren von mit dopaminrezeptor d3 (drd3) verbundenen krankheiten
US20050137186A1 (en) 2003-12-18 2005-06-23 Abbott Gmbh & Co. Kg. Tetrahydrobenzazepines and their use
DE102004027358A1 (de) 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyrimidinverbindungen und ihre Verwendung
JP4904267B2 (ja) * 2004-08-09 2012-03-28 アボット ゲーエムベーハー ウント カンパニー カーゲー ドーパミンｄ３受容体の調節に応答する障害の治療に好適な４−ピペラジニル−ピリミジン化合物
AU2005293693B2 (en) 2004-10-14 2011-11-17 AbbVie Deutschland GmbH & Co. KG 6-amino(aza)indane compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
WO2006040179A1 (en) 2004-10-14 2006-04-20 Abbott Gmbh & Co. Kg Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
KR101315192B1 (ko) 2004-10-14 2013-10-10 애보트 게엠베하 운트 콤파니 카게 도파민 ｄ3 수용체 조절에 반응하는 질환 치료에 적합한헤테로사이클릭 화합물
ES2436178T3 (es) 2004-10-14 2013-12-27 Abbvie Deutschland Gmbh & Co Kg Compuestos aromáticos sustituidos con arilsulfonilmetilo o arilsulfonamida adecuados para tratar trastornos que responden a la modulación del receptor de dopamina D3
US20070293548A1 (en) * 2006-03-31 2007-12-20 Wang Eric Y Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases
KR20090035581A (ko) * 2006-08-04 2009-04-09 아지노모토 가부시키가이샤 신장 기능 장해 예방ㆍ치료제
JPWO2009093471A1 (ja) * 2008-01-25 2011-05-26 学校法人日本大学 アポトーシス抑制薬
KR20190028281A (ko) 2017-09-08 2019-03-18 주식회사 엑소코바이오 지방줄기세포 유래의 엑소좀을 유효성분으로 포함하는 조성물의 신장 기능 개선 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE628766A (no) * 1962-12-26
US3290004A (en) * 1965-04-09 1966-12-06 Hitachi Ltd Device for damping vibration of long steam-turbine blades
DE4223921A1 (de) 1992-07-21 1994-01-27 Hartmut Prof Dr Med Oswald Herstellung und Verwendung von Hemmstoffen der DOPA-Decarboxylase sowie von Dopamin-Rezeptor-Antagonisten zur Bekämpfung der fortschreitenden Verschlechterung der Nierenfunktion beim Menschen
DE4425143A1 (de) * 1994-07-15 1996-01-18 Basf Ag Substituierte Pyrimidinverbindungen und deren Verwendung
DE19600934A1 (de) * 1996-01-12 1997-07-17 Basf Ag Substituierte Aza- und Diazacycloheptan- und Cyclooctanverbindungen und deren Verwendung
DE19922443A1 (de) * 1999-05-07 2000-11-09 Basf Ag Verwendung von Dopamin-D3-Rezeptorliganden zur Herstellung von Arzneimittel für die Behandlung von Nierenfunktionsstörungen

Also Published As

Publication number Publication date
AU4559100A (en) 2000-11-21
ZA200110044B (en) 2003-03-06
CN1360502B (zh) 2010-08-04
NO20015413L (no) 2001-11-15
ATE284693T1 (de) 2005-01-15
CA2368823A1 (en) 2000-11-16
HUP0202399A2 (hu) 2002-12-28
NO329325B1 (no) 2010-09-27
JP2011088941A (ja) 2011-05-06
US20060223793A1 (en) 2006-10-05
US8785447B2 (en) 2014-07-22
PT1176963E (pt) 2005-05-31
JP5542713B2 (ja) 2014-07-09
ES2234597T3 (es) 2005-07-01
DE19922443A1 (de) 2000-11-09
KR100781828B1 (ko) 2007-12-03
HUP0202399A3 (en) 2003-02-28
IL146232A (en) 2007-06-03
KR20070040425A (ko) 2007-04-16
WO2000067847A2 (de) 2000-11-16
KR20010112474A (ko) 2001-12-20
IL146232A0 (en) 2002-07-25
JP2002544178A (ja) 2002-12-24
JP5897054B2 (ja) 2016-03-30
CN1360502A (zh) 2002-07-24
DE50008964D1 (de) 2005-01-20
EP1176963A2 (de) 2002-02-06
AU770671B2 (en) 2004-02-26
CZ301832B6 (cs) 2010-07-07
WO2000067847A3 (de) 2001-08-02
NO20015413D0 (no) 2001-11-06
CZ20014015A3 (cs) 2002-02-13
CN101524356A (zh) 2009-09-09
US7098214B1 (en) 2006-08-29
BR0010337A (pt) 2002-02-13
JP4727822B2 (ja) 2011-07-20
HU228516B1 (en) 2013-03-28
JP2014098044A (ja) 2014-05-29
EP1176963B1 (de) 2004-12-15
CA2368823C (en) 2008-10-21

Similar Documents

Publication Publication Date Title
DK1176963T3 (da) Anvendelse af dopamin-D3-receptorantagonister til fremstilling af lægemidler til behandling af nyrefunktionsforstyrrelser
BG108495A (en) 5-ht receptor ligands and uses thereof
HUP0101690A2 (hu) Onkosztatin-M-antagonista alkalmazása
DE602005015577D1 (de) Harnstoff-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden
NO20034122D0 (no) Sammensmeltede pyridinderivater for anvendelse som vanilloidreseptorantagonister for behandling av smerte
DK1135153T3 (da) Anvendelser af EPH-receptorantagonister og -agonister til behandling af vaskulære forstyrrelser
PA8521501A1 (es) Ligandos para receptores de melanocortina
ATE433966T1 (de) Methylendipiperidinderivate
DE60225673D1 (de) Kappa-opioid-rezeptor-liganden
PT1149078E (pt) Ligandos receptores de 5-ht6 selectivos
ATE346082T1 (de) Glucocorticoidrezeptorliganden zur behandlung von stoffwechselstörungen
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
MX2007006754A (es) Derivados de indenilo y uso de los mismos para el tratamiento de trastornos neurologicos.
PT1853232E (pt) Forma cristalina estável de mesilato de bifeprunox, suas formas de dosagem e métodos para a sua utilização
DK1200073T3 (da) Selektive iGluR5-receptorantagonister til behandling af migræne
DE60305063D1 (de) Ccr1-rezeptor-antagonisten zur behandlung u.a. demyelinisierender entzündlicher erkrankungen
MXPA06000701A (es) Compuestos de sulfonildihidrobencimidazolona como ligandos de 5-hidroxitriptamina-6.
ATE366572T1 (de) 5-ht 1b/1d rezeptor agonisten zur behandlung von kopfschmerz der aus der verabreichung von endothelin rezeptor antagonisten resultiert
DK2001456T3 (da) Anvendelse af kappa-opiodreceptorantagonistholde sammensætninger til behandling af dissociative forstyrrelser
MXPA06000700A (es) Compuestos de sulfonildihidroimidazopiridinona como ligandos de 5-hidroxitriptamina-6.
TR200100240T2 (tr) Anksiyete bozukluklarının tedavisi
PT1143942E (pt) Uso de ligandos de receptores gaba para a manufactura de medicamentos para o tratamento de doencas neurodegenerativas
DK1503764T3 (da) 5-HT4-receptor-antagonister til behandling af hjertesvigt
WO2004067093A3 (en) Nk1 receptor antagonists for the treatment of functional dyspepsia
UA97251C2 (ru) Соединения как модуляторы опиоидного рецептора